IXINITY® MAINTAINS FACTOR IX LEVELS

Clearance and half-life drive high total exposure to factor

The most robust PK parameter for factor treatment is clearance as it is calculated from the area under the curve (AUC), which shows how well therapeutic factor IX levels are maintained.2

24-hour half-life helps patients achieve peak factor levels when they need them. So they don’t have to worry about if—or when—they’re covered.

FACTOR IX AVAILABLE OVER TIME

IXINITY AUC demonstrates prolonged maintenance of therapeutic factor IX levels3*

*The pharmacokinetics of IXINITY have been evaluated in 32 previously treated patients (PTPs) ≥12 years of age with severe to moderately severe hemophilia B.1

ACTIVE FACTOR IN THE BLOODSTREAM

Higher recovery may mean more factor IX on board after infusion

Dose (IU) = body weight x desired factor IX increase x (1/recovery).1

A higher recovery may warrant a dose adjustment. With a higher recovery, more factor is active in the bloodstream, which may allow for lower doses.

†The pharmacokinetics of IXINITY have been evaluated in 32 PTPs ≥12 years of age with severe to moderately severe hemophilia B.1
‡Description is not of an actual patient. Individual dose will vary.

EXPLORE MORE ABOUT IXINITY

Reference: 1. IXINITY [coagulation factor IX (recombinant)] prescribing information. Chicago, IL: Medexus Pharma, Inc.; February 2021. 2. Björkman S. A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing. Haemophilia. 2011;17:179-184.  3. Data on file. Chicago, IL: Medexus Pharma, Inc.